COHANCEPharmaceuticals
COHANCE LIFESCIENCES LTD — Cash Flow Statement
₹301.45
-1.13%
COHANCE LIFESCIENCES LTD Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 132.45 Cr | 332.89 Cr | 171.28 Cr | 254.81 Cr | — |
| Repayment Of Debt | -1.85 Cr | -4.55 Cr | — | — | — |
| Capital Expenditure | -155.71 Cr | -51.88 Cr | -285.91 Cr | -75.19 Cr | — |
| End Cash Position | 85.60 Cr | 47.23 Cr | 64.80 Cr | 44.56 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 0.20 Cr | -1000.00 | — | — | 3000.00 |
| Beginning Cash Position | 47.23 Cr | 64.80 Cr | 44.56 Cr | 7.18 Cr | — |
| Effect Of Exchange Rate Changes | 1.99 Cr | 0.00 | 0.00 | 4000.00 | — |
| Changes In Cash | 36.18 Cr | -17.57 Cr | 20.24 Cr | 37.38 Cr | — |
| Financing Cash Flow | 3.32 Cr | -39.99 Cr | -241.95 Cr | -156.48 Cr | — |
| Interest Paid Cff | -10.43 Cr | -6.95 Cr | -11.56 Cr | -6.23 Cr | — |
| Net Issuance Payments Of Debt | 22.79 Cr | -31.59 Cr | -26.37 Cr | -48.17 Cr | — |
| Net Short Term Debt Issuance | 24.64 Cr | -27.04 Cr | -2.61 Cr | -38.57 Cr | — |
| Net Long Term Debt Issuance | -1.85 Cr | -4.55 Cr | -23.76 Cr | -9.60 Cr | — |
| Long Term Debt Payments | -1.85 Cr | -4.55 Cr | — | — | — |
| Investing Cash Flow | -255.30 Cr | -362.35 Cr | -195.01 Cr | -136.14 Cr | — |
| Interest Received Cfi | 0.23 Cr | 1.93 Cr | 5.83 Cr | 0.07 Cr | — |
| Net Investment Purchase And Sale | 628.15 Cr | -312.40 Cr | 84.45 Cr | -300.27 Cr | — |
| Sale Of Investment | 976.23 Cr | 240.74 Cr | 84.46 Cr | 244.10 Cr | — |
| Purchase Of Investment | -348.08 Cr | -553.14 Cr | -44000.00 | -300.27 Cr | — |
| Net Business Purchase And Sale | -727.97 Cr | 0.00 | 0.00 | 244.10 Cr | — |
| Purchase Of Business | -727.97 Cr | 0.00 | — | — | — |
| Net PPE Purchase And Sale | -155.71 Cr | -51.88 Cr | -285.84 Cr | -75.19 Cr | — |
| Purchase Of PPE | -155.71 Cr | -51.88 Cr | -285.91 Cr | -75.19 Cr | — |
| Operating Cash Flow | 288.16 Cr | 384.77 Cr | 457.20 Cr | 330.00 Cr | — |
| Taxes Refund Paid | -83.44 Cr | -109.95 Cr | -145.76 Cr | -184.26 Cr | — |
| Change In Working Capital | -32.13 Cr | 71.91 Cr | 5.77 Cr | -193.97 Cr | — |
| Change In Payable | 41.71 Cr | -22.52 Cr | -35.80 Cr | 23.20 Cr | — |
| Change In Inventory | 74.12 Cr | 81.61 Cr | -29.39 Cr | -82.34 Cr | — |
| Change In Receivables | -147.96 Cr | 12.82 Cr | 124.47 Cr | -136.09 Cr | — |
| Other Non Cash Items | 9.95 Cr | 4.75 Cr | 5.72 Cr | 6.16 Cr | — |
| Stock Based Compensation | 14.91 Cr | 1.97 Cr | — | — | — |
| Provisionand Write Offof Assets | 0.93 Cr | 0.00 | — | — | — |
| Depreciation And Amortization | 77.49 Cr | 54.60 Cr | 46.46 Cr | 38.26 Cr | — |
| Depreciation | 77.49 Cr | 54.60 Cr | 46.46 Cr | 37.86 Cr | — |
| Gain Loss On Investment Securities | -44.13 Cr | -44.91 Cr | -15.69 Cr | -8.20 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.55 Cr | 0.66 Cr | 0.95 Cr | 4.42 Cr | — |
| Gain Loss On Sale Of PPE | 0.11 Cr | 0.07 Cr | 65000.00 | -6000.00 | — |
| Net Income From Continuing Operations | 343.92 Cr | 405.67 Cr | 559.73 Cr | 667.59 Cr | — |
| Common Stock Dividend Paid | — | 0.00 | -203.65 Cr | -101.83 Cr | -25.46 Cr |
| Net Other Investing Changes | — | 0.04 Cr | 0.55 Cr | -4.84 Cr | -27000.00 |
| Sale Of PPE | — | 0.00 | 0.07 Cr | 6000.00 | 0.03 Cr |
| Change In Other Current Liabilities | — | 2.55 Cr | -16.65 Cr | 9.12 Cr | 4.91 Cr |
| Change In Other Current Assets | — | 11.63 Cr | -35.86 Cr | -10.56 Cr | -13.48 Cr |
| Net Other Financing Charges | — | — | 1000.00 | 0.09 Cr | 0.25 Cr |
| Cash Dividends Paid | — | — | -203.65 Cr | -101.83 Cr | -25.46 Cr |
| Sale Of Business | — | — | 0.00 | 244.10 Cr | — |
| Amortization Cash Flow | — | — | 0.40 Cr | 0.39 Cr | 0.39 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on COHANCE LIFESCIENCES LTD
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.